Rapid Micro Biosystems (NASDAQ:RPID) Upgraded to "Hold" at Wall Street Zen

Key Points

• Rapid Micro Biosystems has been upgraded from a "sell" to a "hold" rating by Wall Street Zen, indicating a shift in analyst sentiment.
• Lake Street Capital initiated coverage with a "buy" rating and an $8.00 target price, contributing to a consensus rating of "Strong Buy" from analysts.
• Shares of Rapid Micro Biosystems experienced a notable range over the past year, with a 52-week low of $0.83 and a high of $4.50, highlighting its volatility in the market.

Rapid Micro Biosystems (NASDAQ:RPID - Get Free Report) was upgraded by equities researchers at Wall Street Zen from a "sell" rating to a "hold" rating in a research note issued to investors on Saturday.

Separately, Lake Street Capital started coverage on Rapid Micro Biosystems in a research report on Monday, July 28th. They issued a "buy" rating and a $8.00 price objective for the company. One research analyst has rated the stock with a Strong Buy rating and one has issued a Buy rating to the company's stock. Based on data from MarketBeat.com, the stock has an average rating of "Strong Buy" and a consensus target price of $8.00.

Rapid Micro Biosystems Stock Performance

NASDAQ:RPID traded up $0.17 during trading hours on Friday, hitting $3.22. The company's stock had a trading volume of 58,554 shares, compared to its average volume of 70,784. The business's 50-day moving average is $3.08 and its two-hundred day moving average is $2.93. The company has a market capitalization of $142.36 million, a PE ratio of -3.19 and a beta of 1.29. Rapid Micro Biosystems has a 52-week low of $0.83 and a 52-week high of $4.50.

Rapid Micro Biosystems (NASDAQ:RPID - Get Free Report) last released its quarterly earnings data on Tuesday, August 12th. The company reported ($0.27) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.26) by ($0.01). The business had revenue of $7.26 million during the quarter, compared to analysts' expectations of $7.10 million. Rapid Micro Biosystems had a negative return on equity of 63.07% and a negative net margin of 145.63%. Rapid Micro Biosystems has set its FY 2025 guidance at EPS. As a group, analysts predict that Rapid Micro Biosystems will post -1.1 EPS for the current fiscal year.

Insider Buying and Selling at Rapid Micro Biosystems

In other news, CEO Robert G. Jr. Spignesi sold 11,881 shares of the firm's stock in a transaction on Monday, July 14th. The stock was sold at an average price of $3.32, for a total value of $39,444.92. Following the completion of the transaction, the chief executive officer owned 970,550 shares in the company, valued at $3,222,226. This trade represents a 1.21% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Insiders sold a total of 57,443 shares of company stock valued at $195,952 in the last three months. Company insiders own 29.96% of the company's stock.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the company. ABG WTT Global Life Science Capital Partners GP Ltd increased its position in shares of Rapid Micro Biosystems by 78.0% in the first quarter. ABG WTT Global Life Science Capital Partners GP Ltd now owns 1,848,296 shares of the company's stock valued at $4,880,000 after buying an additional 810,000 shares in the last quarter. Parkman Healthcare Partners LLC purchased a new position in shares of Rapid Micro Biosystems in the first quarter valued at $1,942,000. Geode Capital Management LLC boosted its stake in shares of Rapid Micro Biosystems by 1.6% during the second quarter. Geode Capital Management LLC now owns 204,079 shares of the company's stock valued at $704,000 after acquiring an additional 3,143 shares during the last quarter. Informed Momentum Co LLC acquired a new stake in shares of Rapid Micro Biosystems during the first quarter valued at $467,000. Finally, Evernest Financial Advisors LLC acquired a new stake in shares of Rapid Micro Biosystems during the first quarter valued at $347,000. Hedge funds and other institutional investors own 52.60% of the company's stock.

Rapid Micro Biosystems Company Profile

Rapid Micro Biosystems, Inc, a life sciences technology company, provides products for the detection of microbial contamination in the manufacture of pharmaceutical, medical devices, and personal care products in the United States, Germany, Switzerland, Japan, and internationally. The company offers Growth Direct platform, which includes Growth Direct system, proprietary consumables, lab information management system connection software, and customer support and validation services.